Stallergenes Greer plc Stallergenes Greer Confirms Appointments to the Board of Directors
12 Dicembre 2018 - 05:00PM
UK Regulatory
TIDM0RB9
Stallergenes Greer (Paris:STAGR), a biopharmaceutical company
specialising in treatments for respiratory allergies, today
announced that the following appointments to the Company's
corporate leadership and Board of Directors were confirmed and
approved by the Company's Board of Directors on 12 December 2018.
Stefan Meister is appointed Chairman of the Board of Directors,
Michele Antonelli is appointed member of the Board of Directors and
Chief Executive Officer and Elmar Schnee is appointed Lead
Independent Director.
The board of directors thanks Fereydoun Firouz, who will retire
from his position as Chairman and Chief Executive Officer at the
end of 2018, for his contribution to the company. Effective 4
January 2019, and as announced in August 2018, Stefan Meister will
take over as Chairman of the board of Directors and Michele
Antonelli as Chief Executive Officer.
Stefan Meister is Group Chief Operating Officer of the Waypoint
Group, a business enterprise for the managers and advisers of the
funds and investments associated with the Bertarelli family, which
is also the indirect owner of Ares Life Sciences I S.a.r.l.,
Stallergenes Greer's largest shareholder. Prior to his role at
Waypoint Group, Mr Meister was Chief Financial Officer of the
Haniel Group, before which he was a member of the Executive
Management Board of Celesio Group. Mr Meister began his career in
1991 at Novartis AG (Switzerland), holding various positions
including Head of Controlling for the Pharma Division. Until May
2016, Mr Meister was a Member of the Board of Directors of the
Swiss group, Straumann. Mr Meister is Swiss and holds a degree in
economics from Basel University.
Michele Antonelli has more than 20 years of international
experience in the biopharmaceutical industry with extensive
expertise in manufacturing, commercial and general management. Mr
Antonelli joined Stallergenes Greer in November 2015 as Executive
Vice President, Head of International Operations. In February 2016,
Mr Antonelli was appointed Executive Vice President, Head of Europe
and International, overseeing both commercial and technical
operations for the Company's Europe and International region.
During the same period he also served as President of Stallergenes
SAS. Prior to Stallergenes Greer, Mr Antonelli worked at UCB, the
multinational biopharmaceutical company, as an Executive Committee
Member where he held roles of various responsibility and scope in
Belgium, Italy and France, most recently serving as Executive Vice
President and Head of Immunology Europe, overseeing the region's
commercial, medical and market access activities. Prior to joining
UCB, Mr Antonelli spent 16 years at Merck Serono, ultimately
serving as Senior Vice President and Global Head of Biotech
Manufacturing and Process Development. He is Swiss and Italian, and
graduated as Doctor in Sciences from University of Bari. He trained
in Biotechnology at Catholic University in Piacenza and at Iowa
State University in Ames, Iowa.
Elmar Schnee has more than 25 years' experience in the
pharmaceutical industry. Mr Schnee is currently Board Secretary of
Mindmaze SA and was, from 2016 to March 2017, Chief Operating
Officer. Mr Schnee is Chairman of the Board of Directors of
Santhera AG, a Swiss speciality pharmaceutical company developing
medicines for rare diseases. He is also a Member of the Board of
Directors of Jazz Pharmaceuticals. From November 2013 to August
2015, Mr Schnee served as a Non-Executive Director of Cardiorentis
Ltd., a biopharmaceutical company, where he served as Chairman and
Chief Executive Officer from October 2011 until November 2013. From
2003 to 2011, Mr Schnee held various positions at Merck KGaA, a
global pharmaceutical and chemical group, having joined in 2003 as
Managing Director of Merck Santé SAS. In 2004, Mr Schnee assumed
responsibility for global commercial operations of the ethical
pharmaceuticals division of Merck KGaA, and in November 2005, Mr
Schnee was appointed as Deputy Member of the Executive Board
responsible for the pharmaceuticals business. In 2006, he was
appointed as a member of the Executive Board and General Partner of
Merck KGaA, with responsibility for global pharmaceutical
activities, and served in this position until 2011. Prior to Merck
KGaA, Mr Schnee held senior positions in strategy, business
development and marketing at UCB SA, Sanofi-Synthélabo SA, Migliara
/ Kaplan Associates, Inc. and Fisons Pharmaceuticals PLC. He
currently serves on the Board of Directors of four privately held
life sciences companies. Mr Schnee holds a BA in marketing and a
masters in marketing and general management from the Swiss
Institute of Business Administration in Zurich.
ABOUT STALLERGENES GREER PLCHeadquartered in London (UK),
Stallergenes Greer plc is a global healthcare company specialising
in the diagnosis and treatment of allergies through the development
and commercialization of allergy immunotherapy products and
services. Stallergenes Greer plc is the parent company of GREER
Laboratories, Inc. (whose registered office is in the US) and
Stallergenes SAS (whose registered office is in France).
TRADING INFORMATIONName: Stallergenes GreerISIN: GB00BZ21RF93 1
- Ticker: STAGRICB Classification: 4577LEI:
213800CYVZA7GJQEME86Market: Euronext Paris regulated market
Further information disclosed pursuant to the AFEP-MEDEF Code
can be found in the Investors section of our website.
Additional information is available at
http://www.stallergenesgreer.com.
This document (including information incorporated by reference
in this document), oral statements made and other information
published by the Company contain statements that are or may be
forward-looking with respect to the financial condition and/or
results of operations and businesses of the Company. These
statements can be identified by the use of forward-looking
terminology such as "believe," "expects," "project," "estimated,"
"forecast," "should," "plan," "may," "will" or the negative of any
of these, or other variations thereof, or comparable terminology
indicating expectations or beliefs concerning future events. These
forward-looking statements include risk and uncertainty because
they relate to events and depend on circumstances that will occur
in the future. Without being exhaustive, such factors include
economic situations and business conditions, including legal and
product evaluation issues, fluctuations in currencies and demand,
and changes in competitive factors. These and other factors are
more fully described in the Company's 2017 annual report published
on 16 April 2018 on the Company's website
www.stallergenesgreer.com. Actual results may differ materially
from those set forth in the forward-looking statements, due to
these and other various factors. Save as required by applicable
law, neither the Company nor any other person assumes any
obligation to update these forward-looking statements or to notify
any person of any such update.
CONTACTS
Investors relations Investor Relations Agency
Matthias Vogt FTI Consulting
Chief Financial Officer Arnaud de Cheffontaines
Office: +44 (0) 207 239 4513 Tel: +33 1 47 03 68 10
Email: Email:
matthias.vogt@stallergenesgreer.com stallergenesgreer@fticonsulting.com
Communications Media Relations Agency
Caitlin Stefanik Havas Paris (Europe)
Communications director Samuel Rousseau
Tel: + 857 331 4117 +33 6 77 88 32 43
Email: E-mail: samuel.rousseau@havas.com
caitlin.stefanik@stallergenesgreer.com
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181212005551/en/
This information is provided by Business Wire
(END) Dow Jones Newswires
December 12, 2018 11:00 ET (16:00 GMT)
Grafico Azioni Stallergenes Greer (LSE:0RB9)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Stallergenes Greer (LSE:0RB9)
Storico
Da Mar 2023 a Mar 2024